 |
|
Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
Warfarin, Aspirin, or Both?
Arch Intern Med. 1998;158:1487-1491.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
IN THE PAST DECADE, definitive evidence has emerged from multiple randomized clinical trials that establishes adjusted-dose oral anticoagulants (target international normalized ratio of prothrombin time [INR], approximately 2.0-3.0) as highly effective and safe therapy for prevention of stroke in patients with atrial fibrillation.1 Since 1992, several authoritative groups, including the American College of Chest Physicians, American Heart Association, and American College of Physicians have strongly and repeatedly recommended that most patients with atrial fibrillation be prescribed adjusted-dose warfarin sodium therapy.2-5 Despite compelling data and definitive recommendations, most of these patients are not receiving oral anticoagulation therapy. Although aspirin is less effective than warfarin for stroke prevention in these patients, it continues to be commonly prescribed, and a substantial number of eligible patients with atrial fibrillation receive no antithrombotic therapy.6-7
Underuse of warfarin for patients with atrial fibrillation has been attributed to numerous factors, including physician reluctance to prescribe a medication . . . [Full Text of this Article] IS LOW-INTENSITY, FIXED-DOSE WARFARIN EFFECTIVE FOR STROKE PREVENTION?
DOES ASPIRIN IMPROVE THE EFFICACY OF LOW-INTENSITY, FIXED-DOSE WARFARIN?
WHICH PATIENTS ARE APPROPRIATE CANDIDATES FOR ASPIRIN THERAPY?
CHOICE OF ANTITHROMBOTIC THERAPY FOR PATIENTS WITH ATRIAL FIBRILLATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
Annette Lemche Gulløv, Birgitte Gade Koefoed, Palle Petersen, Trine Sander Pedersen, Ellen Damgaard Andersen, John Godtfredsen, and Gudrun Boysen
Arch Intern Med. 1998;158(14):1513-1521.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Healey et al.
Stroke 2008;39:1482-1486.
ABSTRACT
| FULL TEXT
Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin
Gage et al.
Circulation 2004;110:2287-2292.
ABSTRACT
| FULL TEXT
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation: An Individual Patient Meta-analysis
van Walraven et al.
JAMA 2002;288:2441-2448.
ABSTRACT
| FULL TEXT
Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
Kalra et al.
BMJ 2000;320:1236-1239.
ABSTRACT
| FULL TEXT
The Quality of Anticoagulation Management
Ansell
Arch Intern Med 2000;160:895-896.
FULL TEXT
IMPACT OF THE MAZE PROCEDURE ON THE STROKE RATE IN PATIENTS WITH ATRIAL FIBRILLATION
Cox et al.
J. Thorac. Cardiovasc. Surg. 1999;118:833-840.
ABSTRACT
| FULL TEXT
State-of-the-Art Review: Warfarin Therapy: A Review of the Literature Since the Fifth American College of Chest Physicians' Consensus Conference on Antithrombotic Therapy
Lodwick
CLIN APPL THROMB HEMOST 1999;5:208-215.
Warfarin vs Aspirin and AFASAK 2
Bloom et al.
Arch Intern Med 1999;159:1010-1011.
FULL TEXT
|
